Abakavir/lamivudin

Abakavir/lamivudin
Klinički podaci
Drugs.com	Monografija
Identifikatori
ATC kod	J05AR02 (WHO)
PubChem	CID 5273759
Hemijski podaci
Formula	C22H29N9O4S
Molarna masa	515,59 g·mol−1
	SMILES NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2.Nc3nc(NC4CC4)c5ncn([C@@H]6C[C@H](CO)C=C6)c5n3; ;
	InChI InChI=1S/C14H18N6O.C8H11N3O3S/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);1-2,6-7,12H,3-4H2,(H2,9,10,13)/t8-,10+;6-,7+/m10/s1; Key:UGWQMIXVUBLMAH-IVVFTGHFSA-N ;

Abakavir/lamivudin je kombinovani lek koji se koristi radi tretmana HIV infekcije.^[1]^[2] Prodaje se pod nazivom Kivexa u većini zemalja, osim u Sjedinjenim državama gde je brendiran kao Epzicom.^[3]

Lamivudin i abakavir su nukleozidni inhibitori reverzne transkriptaze.

Od 2015. godine, troškovi tipičnog mesečnog lečenja ovim lekom u Sjedinjenim državama bili su veći od $200.^[4] U Srbiji, lek se pod robnim imenom Kivexa nalazi na listi lekova koji se propisuju i izdaju na obrascu lekarskog recepta Republičkog fonda za zdravstveno osiguranje. Cena leka na veliko za pakovanje od 30 film tableta iznosi preko 36 hiljada dinara.^[5]

Osobine

Abakavir/lamivudin je organsko jedinjenje, koje sadrži 22 atoma ugljenika i ima molekulsku masu od 515,589 Da.

Osobina	Vrednost
Broj akceptora vodonika	12
Broj donora vodonika	5
Broj rotacionih veza	6
Particioni koeficijent^[6] (ALogP)	0,2
Rastvorljivost^[7] (logS, log(mol/L))	-4,4
Polarna površina^[8] (PSA, Å²)	215,3

Reference

^ Smith, Kimberly Y; Patel, Parul; Fine, Derek; Bellos, Nicholaos; Sloan, Louis; Lackey, Philip; Kumar, Princy N; Sutherland-Phillips, Denise H; Vavro, Cindy; Yau, Linda; Wannamaker, Paul; Shaefer, Mark S (2009). „Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment”. AIDS. 23 (12): 1547—1556. doi:10.1097/QAD.0b013e32832cbcc2.
^ Post, Frank A; Moyle, Graeme J; Stellbrink, Hans Jürgen; Domingo, Pere; Podzamczer, Daniel; Fisher, Martin; Norden, Anthony G; Cavassini, Matthias; Rieger, Armin; Khuong-Josses, Marie-Aude; Branco, Teresa; Pearce, Helen C; Givens, Naomi; Vavro, Cindy; Lim, Michael L (2010). „Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study”. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55 (1): 49—57. doi:10.1097/QAI.0b013e3181dd911e.
^ „ViiV Healthcare: Kivexa”. Архивирано из оригинала 07. 12. 2009. г. Приступљено 02. 11. 2016.
^ Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. стр. 59. ISBN 9781284057560.
^ „Важећа Листа лекова”. Архивирано из оригинала 04. 11. 2016. г. Приступљено 02. 11. 2016.
^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Abacavir/lamivudine

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Smith, Kimberly Y; Patel, Parul; Fine, Derek; Bellos, Nicholaos; Sloan, Louis; Lackey, Philip; Kumar, Princy N; Sutherland-Phillips, Denise H; Vavro, Cindy; Yau, Linda; Wannamaker, Paul; Shaefer, Mark S (2009). „Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment”. AIDS. 23 (12): 1547—1556. doi:10.1097/QAD.0b013e32832cbcc2.

[2] Post, Frank A; Moyle, Graeme J; Stellbrink, Hans Jürgen; Domingo, Pere; Podzamczer, Daniel; Fisher, Martin; Norden, Anthony G; Cavassini, Matthias; Rieger, Armin; Khuong-Josses, Marie-Aude; Branco, Teresa; Pearce, Helen C; Givens, Naomi; Vavro, Cindy; Lim, Michael L (2010). „Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study”. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55 (1): 49—57. doi:10.1097/QAI.0b013e3181dd911e.

[3] „ViiV Healthcare: Kivexa”. Архивирано из оригинала 07. 12. 2009. г. Приступљено 02. 11. 2016.

[Ric2015-4] Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. стр. 59. ISBN 9781284057560.

[5] „Важећа Листа лекова”. Архивирано из оригинала 04. 11. 2016. г. Приступљено 02. 11. 2016.

[6] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.

[7] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[8] Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]